ATE404211T1 - Xenon als nmda-antogonist zur neuroprotektion - Google Patents

Xenon als nmda-antogonist zur neuroprotektion

Info

Publication number
ATE404211T1
ATE404211T1 AT00948171T AT00948171T ATE404211T1 AT E404211 T1 ATE404211 T1 AT E404211T1 AT 00948171 T AT00948171 T AT 00948171T AT 00948171 T AT00948171 T AT 00948171T AT E404211 T1 ATE404211 T1 AT E404211T1
Authority
AT
Austria
Prior art keywords
xenon
nmda
antogonist
neuroprotection
modulating
Prior art date
Application number
AT00948171T
Other languages
English (en)
Inventor
Nicholas P Franks
Mervyn Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10858166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE404211(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of ATE404211T1 publication Critical patent/ATE404211T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00948171T 1999-07-29 2000-07-28 Xenon als nmda-antogonist zur neuroprotektion ATE404211T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9917822.0A GB9917822D0 (en) 1999-07-29 1999-07-29 Nmda antagonist

Publications (1)

Publication Number Publication Date
ATE404211T1 true ATE404211T1 (de) 2008-08-15

Family

ID=10858166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948171T ATE404211T1 (de) 1999-07-29 2000-07-28 Xenon als nmda-antogonist zur neuroprotektion

Country Status (13)

Country Link
US (1) US6274633B1 (de)
EP (1) EP1200103B1 (de)
JP (1) JP5088997B2 (de)
AT (1) ATE404211T1 (de)
AU (1) AU778097B2 (de)
CA (1) CA2280310C (de)
DE (1) DE60039878D1 (de)
ES (1) ES2311466T3 (de)
GB (1) GB9917822D0 (de)
PT (1) PT1200103E (de)
RU (1) RU2257902C2 (de)
WO (1) WO2001008692A1 (de)
ZA (1) ZA200200539B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US7097849B2 (en) 1998-08-19 2006-08-29 Jagotec Ag Injectable aqueous dispersions of propofol
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
GB0210021D0 (en) * 2002-05-01 2002-06-12 Air Prod & Chem Ultrasonic gas analyser
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
US7337776B2 (en) * 2002-08-20 2008-03-04 Aga Ab Methods for easing pain and anxiety from atrial or ventricular defibrillation
US7681572B2 (en) * 2002-08-20 2010-03-23 Aga Ab Method and devices for administration of therapeutic gases
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
PT1670489E (pt) * 2003-10-10 2008-02-28 Protexeon Ltd Utilização de xénon com hipotermia para o tratamento de asfixia neonatal
US20080031971A1 (en) * 2003-10-21 2008-02-07 Aga Ab Use Of Xenon For The Prevention Of Programmed Cell Death
FR2863169B1 (fr) * 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
RU2346695C2 (ru) * 2006-08-15 2009-02-20 Общество с ограниченной ответственностью "Ксиан"(ООО "Ксиан") Применение ксенона для коррекции патологических изменений в организме, связанных с нарушением антиоксидантного статуса
EP1980261A1 (de) 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung von Helium mit Sauerstoff zur Bereitstellung von Neuroprotektion
EP1980260A1 (de) 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung hyperbarischer Bedingungen zur Bereitstellung von Neuroprotektion
US8435569B2 (en) * 2007-04-30 2013-05-07 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (A) and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
FR2952305B1 (fr) * 2009-11-10 2012-04-27 Air Liquide Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
JP6625966B2 (ja) 2013-03-15 2019-12-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 希ガスが豊富な液体ならびにその調製及び使用の方法
FR3022456B1 (fr) * 2014-06-20 2016-07-15 Air Liquide Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU120307A1 (ru) * 1949-04-19 1958-11-30 К.М. Салдадзе Способ приготовлени искусственно-радиоактивных лечебных ванн
SU1075632A1 (ru) * 1982-05-25 1985-06-30 Ордена Трудового Красного Знамени Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Устройство дл моделировани нейрона
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
ATE229004T1 (de) * 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
JPH1171271A (ja) * 1997-06-27 1999-03-16 Shionogi & Co Ltd グルコン酸又はその類縁体を含有するｎｍｄａ受容体拮抗剤
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen

Also Published As

Publication number Publication date
ES2311466T3 (es) 2009-02-16
CA2280310C (en) 2008-10-14
ZA200200539B (en) 2002-09-25
US6274633B1 (en) 2001-08-14
PT1200103E (pt) 2008-09-17
GB9917822D0 (en) 1999-09-29
RU2257902C2 (ru) 2005-08-10
JP2003505512A (ja) 2003-02-12
CA2280310A1 (en) 2001-01-29
JP5088997B2 (ja) 2012-12-05
WO2001008692A1 (en) 2001-02-08
EP1200103A1 (de) 2002-05-02
EP1200103B1 (de) 2008-08-13
AU778097B2 (en) 2004-11-18
AU6173500A (en) 2001-02-19
DE60039878D1 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
DE60039878D1 (de) XENON ALS NMDA-ANTOGONIST zur Neuroprotektion
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
SE9503924D0 (sv) Novel opioid peptides
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
SE9904505D0 (sv) Novel compounds
DE602005001445D1 (de) N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
MXPA01012882A (es) Composiciones y metodos que comprenden gluconato de morfina.
SE0100569D0 (sv) New compounds
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
EP1213031A3 (de) Kombinationstherapie zur Behandlung von Depression, Angstzuständen und Psychosen, die ein antidepressives und/oder anxiolytisches Mittel und einen D4-Rezeptor-Hemmer enthält
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
TW200606164A (en) New compounds
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
MY141756A (en) Use of phenoxyacetic acid derivatives for treating hyperactive bladder
ATE259784T1 (de) Propanolaminotetraline, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen
YU59102A (sh) JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR
EP1260221A3 (de) Kombinationsbehandlung für Depression und Angstzustände
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
MX2007002532A (es) Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.
WO2002049624A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und dopamin-agonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties